Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Michael J. Santostefano"'
Autor:
Sarah R, Nesfield, Thomas C, Williams, Debie J, Hoivik, Richard T, Miller, Jane S, Allen, Krzysztof, Selinger, Douglas, Rickert, Michael J, Santostefano
Publikováno v:
International Journal of Toxicology. 24:341-348
This study was conducted in support of the International Life Sciences Institute (ILSI) alternative carcinogenicity models initiative to evaluate the carcinogenic potential of clofibrate, a nongenotoxic peroxisome proliferator-activated receptor (PPA
Autor:
Carla E, Torrey, Henry G, Wall, James A, Campbell, Puntipa, Kwanyuen, Debie J, Hoivik, Richard T, Miller, Jane S, Allen, Manuel J, Jayo, Krzysztof, Selinger, Michael J, Santostefano
Publikováno v:
International Journal of Toxicology. 24:327-339
This study was conducted as part of the International Life Sciences Institute (ILSI) Alternatives to Carcinogenicity Testing program and evaluated the carcinogenic potential of clofibrate, a nongenotoxic, peroxisome proliferator-activated receptor (P
Autor:
Carla E, Torrey, James A, Campbell, Debie J, Hoivik, Richard T, Miller, Jane S, Allen, Peter C, Mann, Krzysztof, Selinger, Douglas, Rickert, Paul M, Savina, Michael J, Santostefano
Publikováno v:
International Journal of Toxicology. 24:289-299
This study was conducted as part of International Life Sciences Institute (ILSI) program to evaluate the carcinogenic potential of clofibrate, a nongenotoxic, peroxisome proliferator-activated receptor (PPAR) α agonist, following oral administration
Autor:
Jane S. Allen, Michael J. Santostefano, Sarah R. Nesfield, Debie J. Hoivik, Douglas Rickert, Thomas C. Williams, Krzysztof Selinger, Richard T. Miller
Publikováno v:
International Journal of Toxicology. 24:301-311
The purpose of the study was to support of the International Life Sciences Institute (ILSI) alternative carcinogenicity models initiative to evaluate the carcinogenic potential of the nongenotoxic carcinogen, clofibrate, a peroxisome proliferator-act
Publikováno v:
Toxicological Sciences. 56:49-60
A physiologically based pharmacodynamic (PBPK) model for 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) was developed based on pharmacokinetic data from acute oral exposures of TCDD to female Sprague-Dawley rats (Wang et al., 1997, Toxicol Appl. Pharmac
Publikováno v:
Biochemical and Biophysical Research Communications. 252:225-231
The aryl hydrocarbon receptor (AhR) shares a common PAS domain with a number of genes that exhibit a pronounced circadian rhythm. Therefore, this study examined the daily cycle of AhR and AhR nuclear translocator (Arnt) protein expression in multiple
Autor:
Xiaofeng Wang, Michael J. Santostefano, David G. Ross, Linda S. Birnbaum, Vicki M. Richardson, Michael J. DeVito
Publikováno v:
Toxicology and Applied Pharmacology. 151:294-310
The ability of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) to alter gene expression and the demonstration that the induction of CYP1A2 is responsible for hepatic TCDD sequestration suggest that both pharmacokinetic and pharmacodynamic events m
Autor:
Krista L. Johnson, Michael J. DeVito, Linda S. Birnbaum, Janet J. Diliberto, Vicki M. Richardson, Michael J. Santostefano, Nicole A. Whisnant
Publikováno v:
Fundamental and Applied Toxicology. 34:265-275
Subcellular localization of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds has been examined only in the liver. The objective of this study was (1) to examine and compare the subcellular distribution of TCDD within hepatic and nonhe
Autor:
MICHAEL J. SANTOSTEFANO, KRISTA L. JOHNSON, NICOLE A. WHISNANT, VICKI M. RICHARDSON, MICHAEL J. DEVITO, LINDA S. BIRNBAUM
Publikováno v:
Toxicological Sciences. 34:265-275
Autor:
Dan A. Rock, Wei-Jian Pan, Michael J. Santostefano, Hugo M. Vargas, James F. Reindel, Duc Tran, Madeline M. Fort, Kai O. Reynhardt, Jacqueline A. Kirchner, Padma K. Narayanan, Remi Jawando, William A. Rees, Nancy E. Everds, Peter J. Prince, Sean Lear, Kelly Hensley, Christine Vissinga
Publikováno v:
Toxicologic pathology. 40(6)
AMG X, a human neutralizing monoclonal antibody (mAb) against a soluble human protein, caused thrombocytopenia, platelet activation, reduced mean arterial pressure, and transient loss of consciousness in cynomolgus monkeys after first intravenous adm